在败血症中,METTL3通过调节SIRT1介导的HMGB1释放来抑制炎症反应
Lijuan Zhang1, Fangqing Zuo1, Junda Li1
1Institute of Burn Research, Southwest Hospital & State Key Lab of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Wound Repair and Tissue Regeneration, Third Military Medical University (Army Medical University), Chongqing, 400038, PR China.
European journal of pharmacology
|July 18, 2025
概括
甲基转移酶样3 (METTL3) 通过控制N6-甲基氨酸 (m6A) RNA修饰来调节败血症中的炎症. 通过稳定SIRT1mRNA,减少炎症性HMGB1释放,METTL3可以防止败血症.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 败血症是一种危及生命的疾病,其特征是受炎症失调.
- N6-甲基氨酸 (m6A) 是一个关键的RNA修饰,由编写器,擦拭器和阅读器调节.
- 对于METTL3,一个m6A编辑器在败血症发病过程中的作用尚不清楚.
研究的目的:
- 调查METTL3介导的m6A修饰在败血症相关炎症中的功能.
- 阐明METTL3影响败血症的分子机制.
- 探索METTL3作为毒症的潜在治疗点.
主要方法:
- 在患者和动物样本中对m6A水平和METTL3表达的定量分析.
- 在体外研究中使用脂多糖 (LPS) 激活的RAW264.7细胞.
- 在体内败血症模型评估METTL3.3的影响.
- 对SIRT1/HMGB1轴和YTHDC1参与的调查.
主要成果:
- 败血症患者,败血动物和LPS激活细胞显示m6A和METTL3水平降低.
- 过度表达METTL3抑制了炎症反应和HMGB1分泌.
- 通过调节SIRT1/HMGB1轴,METTL3在体内显示出保护作用.
- 通过YTHDC1,METTL3增强了SIRT1mRNA的稳定性,减少了细胞外HMGB1.1.
结论:
- METTL3在缓解败血症引起的炎症方面发挥着至关重要的作用.
- METTL3-SIRT1/HMGB1通路是败血症炎症解决的关键机制.
- METTL3代表了治疗败血症治疗的有前途的治疗标.
相关概念视频
Inflammatory Response
7.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
7.7K
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K


